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Mitochondria are involved in crucial homeostatic process-
es in the cell: the production of adenosine triphosphate 
and reactive oxygen species, and the release of pro-apop-
totic molecules. Thus, cell survival depends on the mainte-
nance of proper mitochondrial function by mitochondrial 
quality control. The most important mitochondrial quality 
control mechanisms are mitochondrial unfolded protein 
response, mitophagy, biogenesis, and fusion-fission dy-
namics. This review deals with mitochondrial quality con-
trol in heart diseases, especially myocardial infarction and 
heart failure. Some previous studies have demonstrated 
that the activation of mitochondrial quality control mech-
anisms may be beneficial for the heart, while others have 
shown that it may lead to heart damage. Our aim was to 
describe the mechanisms by which mitochondrial quality 
control contributes to heart protection or damage and to 
provide evidence that may resolve the seemingly contra-
dictory results from the previous studies.
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Mitochondria are involved in adenosine triphosphate (ATP) 
generation, biosynthetic processes and redox homeosta-
sis. However, dysfunctional mitochondria can become a 
source of endogenous noxious stimuli that can severely 
damage the cells, such as the overproduction of reactive 
oxygen species (ROS), cellular calcium overload, opening 
of mitochondrial permeability transition pore (mPTP), and 
release of pro-apoptotic signals (1,2). Thus, it is of vital im-
portance to maintain mitochondrial function by (intra)mi-
tochondrial quality control (MQC) mechanisms. MQC either 
repairs the damaged mitochondria by restoring or destroy-
ing impaired proteins through the activation of mitochon-
drial unfolded protein response (UPRmt), or removes mi-
tochondria damaged beyond repair by mitophagy (3). 
Mitophagy is closely balanced with mitochondrial biogen-
esis to maintain total mitochondrial mass. Rapid changes 
in fusion and fission of mitochondria are associated with 
ROS generation and apoptosis, but are also interconnect-
ed with other MQC mechanisms (4).
Cardiovascular diseases, especially acute myocardial infarc-
tion (MI) and chronic heart failure (HF), account for numer-
ous deaths and severely undermine the quality of life (5,6). 
A crucial etiological factor in these diseases is mitochon-
drial dysfunction (7). The aim of this article is to review the 
present data on underlying mechanisms of heart disease, 
especially HF and MI, mediated by improper MQC function-
ing. While the broad scientific community recognizes MQC 
as a beneficial homeostatic mechanism, numerous studies 
demonstrate its opposite effects on cardiac diseases. Some 
studies report a cardioprotective role of MQC, while others 
show its negative effects in major heart disease. Here, we 
will try to provide a plausible explanation of such discrep-
ancies. The article addresses major components of MQC in 
heart disease, including UPRmt, mitophagy, mitochondri-
al biogenesis, and mitochondrial fusion-fission, as well as 
MQC in the aged heart.
BASIC MECHANISMS OF INJURY IN MYOCARDIAL 
INFARCTION AND HEART FAILURE
The common noxious stimuli in MI and HF are excessive ROS 
generation and mitochondrial calcium overload (1,2,8,9). In 
both diseases, ROS and mitochondrial calcium overload in-
duce opening of the mPTP, which ultimately leads to apop-
totic or necrotic cell death (1,2,10). Mitochondrial permea-
bility transition pore opening initiates the events that lead 
to the release of intramitochondrial proapoptotic factors, 
including cytochrome c, diablo IAP-binding mitochondrial 
protein, HTRA serine peptidase 2 [OMI/HTRA2], apoptosis-
inducing factor, and endonuclease G (11). It is believed that 
a less extensive mPTP opening results in apoptosis, mostly 
in the periphery of MI (12). More extensive mPTP opening 
in the center of MI leads to necrotic cell death, possibly 
due to severe ATP depletion and the inability to complete 
the energy-dependent process of apoptosis (12). A major 
role in the pathogenesis of heart injury is played by the 
substrates used for energy metabolism. For example, the 
use of fatty acids can enhance ROS generation and thereby 
damage cardiomyocytes (13).
MITOCHONDRIAL UNFOLDED pROTEIN RESpONSE
UPRmt is evolutionally a highly conserved MQC mecha-
nism that helps maintain normal mitochondrial function 
under pathological conditions (Figure 1). It can be triggered 
by damage to mitochondrial proteins, imbalance between 
mitochondrial and nuclear proteome (mitonuclear imbal-
ance), or other stressors, such as mitochondrial depolariza-
tion. UPRmt and endoplasmic reticulum UPR share some 
elements, especially transcription factors such as C/EBP 
homologous protein (CHOP), CCAAT/enhancer-binding 
protein β (C/EBPβ), or eukaryotic initiation factor 2α (eIF2α) 
(14,15). UPRmt involves a complex machinery of signaling 
molecules, transcription factors, proteases (OMI/HTRA2, 
lon peptidase 1 [LONP1], caseinolytic mitochondrial ma-
trix peptidase proteolytic subunit [ClpP], paraplegin, YME1 
like 1 ATPase [YME1L], mitochondrial-processing peptidase 
[MPP], and OMA1 zinc metallopeptidase [OMA1]), antioxi-
dants (thioredoxin 2), endonuclease G, and chaperons (mi-
tochondrial 70kDa heat shock protein, heat shock protein 
family D [Hsp60] member 1, heat shock protein family E 
[Hsp10] member 1, and DnaJ [Hsp40] homologue, sub-
family A, member 3) (16-19). The peptides obtained by mi-
tochondrial proteases are extruded from mitochondria by 
HAlF transporter (ATP Binding Cassette Subfamily B Mem-
ber 10 in mammals), further activating transcription factors 
CHOP, C/EBPβ, and activating transcription factor 4 (ATF-4) 
via c-Jun/AP-1 (14,15).
One of the important mechanisms that may regulate 
UPRmt consists of mutually-dependent activity of two an-
tagonistic mitochondrial proteases, YME1L and OMA1. Hu-
man ATP-dependent YME1L is an orthologue of the YME1 
subunit of the yeast i-AAA complex, and OMA1 is a zinc 
metallopeptidase. Depending on the conditions within 
the cell, the two proteases can cleave and inactivate each 
other (20). YME1L up-regulation will result in OMA1 inac-
tivation, and vice versa. Both YME1L and OMA1 can be 
up-regulated by stress. Constitutively active YME1L 
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FIgURE 1. Mitochondrial quality control (MQC) in heart disease. Everyday moderate stress/damage to mitochondria is repaired by 
MQC mechanisms (blue arrow), which prevent the occurrence of dysfunctional mitochondria that may exacerbate stress/damage. 
Less extensive damage is repaired by mitochondrial unfolded protein response (UpRmt), which properly folds misfolded proteins 
(chaperons) or cleaves them (proteases). Mitochondria that are beyond repair undergo mitophagy, which is tightly associated 
with mitochondrial biogenesis, serving to maintain a pool of healthy mitochondria. Mitochondrial fusion is beneficial as it reduces 
reactive oxygen species (ROS) generation. Mitochondrial fission promotes healthy phenotype when allowing mitophagy. Extreme 
stress beyond compensation by MQC systems induces mitochondrial permeability transition pore (mpTp) opening and cardiomyo-
cytes death (solid red arrows). Less pronounced mpTp opening allows cell death by apoptosis, which is dominant in heart failure. 
The most extensive cell stress induces widespread mpTp opening in cardiomyocytes, which leads to necrotic cell death, a predomi-
nant mechanism in acute ischemia-reperfusion, ie, myocardial infarction. Extremely high cell stresses are linked to mitochondrial 
fission, which exacerbates ROS generation. Inadequate MQC system activation induces cell death even during exposure to less 
extensive cell stress (red dotted arrows). This includes excessive activation of either UpRmt, mitophagy, or mitochondrial fission, 
which cause further dysfunction of mitochondria, or insufficient activation of MQC mechanisms that do not repair/eliminate 
dysfunctional mitochondria.
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is further activated by mitochondrial depolarization with 
preserved ATP levels, while OMA1, which is quiescent in 
non-stressed cells, is activated by mitochondrial depolar-
ization with ATP loss (20). In addition, YME1L may also be 
inactivated by high oxidative stress, which promotes cell 
death (21). Although the majority of studies indicate a neg-
ative effect of Oma1 on mitochondrial function and cel-
lular viability, Bohovych (22) showed that OMA1 deletion 
impeded the stability of respiratory chain supercomplex-
es and mitochondrial bioenergetics in mouse embryonic 
fibroblasts. In the active state, YME1L triggers UPRmt by 
cleaving mitochondrial proteins and creating mitonuclear 
protein imbalance (23). The loss of activity of YME1L im-
pairs normal mitochondrial fusion-fission dynamic, which 
is associated with an increase in ROS generation and in-
crease in sensitivity to oxidative stress. This is caused by the 
up-regulation of OMA1 and OMA1-induced cleavage/inac-
tivation of pro-fusion OPA1 (24). The loss of YME1L decreas-
es cell proliferation, diminishes resistance to apoptosis, and 
increases protein carbonylation (16).
The beneficial effects of UPRmt are reflected in the preser-
vation of ATP production, attenuation of excess mitochon-
drial ROS emission, and prevention of release/activation of 
mitochondrial pro-apoptotic factors (25). UPRmt-inducing 
transcription factor ATFS-1 promotes the assembly of oxi-
dative phosphorylation components during mitochon-
drial stress, which can preserve ATP production (26). At 
the same time, UPRmt proteases, such as YME1L (16) or 
ClpP (17), can cleave dysfunctional respiratory chain com-
ponents. Thus, UPRmt promotes respiratory chain recov-
ery and helps maintaining oxidative phosphorylation in 
stressed mitochondria via ATFS-1 actions. However, ClpP 
hyperactivation by ONC201 (imipiridone) treatment dimin-
ishes oxidative phosphorylation and induces cell death in 
cancer cells (17).
Mitochondrial unfolded protein response in heart 
disease
UPRmt is protective in chronic (27) and acute cardiac injury 
(18). However and seemingly contradictory, studies have 
also found that blocking several UPRmt elements can re-
duce the signs of HF of a different etiology.
One of key breakthroughs delineating the role of mito-
chondria in HF was a recent publication by Wai et al, who 
showed that cardiac-specific YME1L deletion caused HF 
and premature death of mice (28). An additional OMA1 
deletion restored normal mitochondrial morphology and 
rescued the mice from HF and premature death. However, 
OMA1 deletion was also shown to cause developmental 
heart defects (22), indicating the importance of fine tuning 
of UPRmt effector proteases for cardiac viability. The activ-
ity of another component of UPRmt, LONP1, reduced by 
oxidative stress leads to the accumulation of dysfunction-
al respiratory chain subunits and left ventricle contractile 
dysfunction (29). On the other hand, LONP1 up-regulation 
protects cardiomyocytes from ischemia-reperfusion (I/R) 
injury (18). Moreover, the down-regulation of endonu-
clease G contributes to ROS overproduction, reduces mi-
tochondrial DNA replication, and induces cardiac hyper-
trophy in rodents (19).
Conversely, there is evidence that UPRmt can be associ-
ated with harmful events in the heart. Physical exercise 
reduces CCAAT/enhancer-binding protein β expression 
in mice, and its reduction is associated with neonatal car-
diomyocyte proliferation and improved resistance to pres-
sure-induced hypertrophy (14). Furthermore, excessive 
eIF2α activation via double-stranded RNA-dependent pro-
tein kinase (PKR) promotes cardiomyocyte apoptosis and 
HF (30). Parvostatin blocks UPRmt activator c-Jun, which 
improves left ventricular function and slows the progres-
sion of HF in mice (31). Moreover, elevated LONP1 activity 
is a mediator of hypoxia-induced cardiomyocyte apoptosis 
and its down-regulation attenuates ROS generation and 
protects the cells (32), while ClpP deletion increases the 
expression of respiratory chain subunits and reduces car-
diomyopathy (33). In the aged rat heart, the elevated activ-
ity of OMI/HTRA2 protease promotes mitochondrial depo-
larization and apoptosis (34), and its overexpression causes 
apoptosis and cardiac dysfunction in transgenic mice (35). 
Gain-of-function mutation of paraplegin (SPG7) increases 
mitochondrial ROS generation and coronary artery dis-
ease risk (36). Lin et al (37) linked high HSP60 expression to 
proinflammatory state and cardiomyocyte damage in hu-
man HF. Elevated expression/activity of several UPRmt ele-
ments was demonstrated in humans and animals with HF, 
including LON and ClpP (38), CHOP (15), eIF2α (15), ATF-4 
(39), and c-Jun N-terminal kinases (40).
A potential explanation for such seemingly contradictory 
findings is that UPRmt is cardioprotective when moder-
ately active, while its excessive activity may be cardiotoxic. 
A moderate activation of UPRmt may be beneficial for re-
moving/repairing damaged mitochondrial proteins and 
thereby maintaining normal mitochondrial and cardiac 
function. An excessive UPRmt activation could result in 
a massive cleavage of mitochondrial proteins, exac-
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erbating mitochondrial dysfunction and promoting heart 
damage. It is difficult to discriminate cardiotoxic from car-
dioprotective actions of UPRmt in the absence of reliable 
pharmacological inhibitors/activators and using only gene 
overexpression/knockouts models, which are not well suit-
ed for testing fine dose-responses.
MITOpHAgY
Mitochondrial damage with the loss of polarity on the outer 
mitochondrial membrane (OMM) is a signal for the removal 
of mitochondria by mitochondrial autophagy (mitophagy). 
The complex processes involved in mitophagy are in more 
detail described elsewhere (3). Mitochondrial fragmenta-
tion is essential for mitophagy, whereby fission enables 
the sequestration of damaged mitochondrial parts into a 
mitochondrion, which is eliminated by mitophagy. Crucial 
molecular regulators of mitophagy are Parkin (E3 ubiquitin 
ligase) and PTEN-induced putative kinase protein 1 (PINK1) 
(41,42). Under normal conditions, when mitophagy is not 
occurring, Parkin is self-ubiquitinated and inactivated and 
PINK1 is degraded (3,24). PINK1 is degraded by MPP and 
presenilin-associated rhomboid-like (PARL) after it is im-
ported into the mitochondrial matrix via the translocase of 
the outer membrane 40 and translocase of the inner mem-
brane 23 complexes (24). The loss of mitochondrial mem-
brane potential prevents the import of PINK1, which then 
accumulates in the TOM complex. PINK1 autophosphory-
lates and activates itself and phosphorylates and activates 
Parkin. Parkin ubiquitinates mitochondrial OMM proteins 
and thereby targets them for phagosomal digestion. In the 
process of mitophagy, Parkin also interacts with PRKR-like 
endoplasmic reticulum kinase, ATF-4, MFN2, mitochondri-
al rho GTPase 1, voltage-dependent anion-selective chan-
nel 1, and hexokinase-1 (3,39,43). The mitochondrion is 
engulfed by the autophagosome, which eventually fuses 
with lysosome for digestion. The autophagosome forma-
tion depends on the proteins optineurin, nuclear domain 
10 protein 52, sequestosome 1 (p62), microtubule-associ-
ated proteins 1A/1B light chain 3B (LC3), and TANK-binding 
kinase 1 (3,42). The phagophore membrane elongation is 
conveyed by proteins from the autophagy-related genes 
(ATG) family. An important factor in autophagosome for-
mation is unc-51 like autophagy activating kinase 1 com-
plex. It phosphorylates a large number of mitophagy pro-
teins, such as Beclin-1, p62 and FUN14 domain containing 
1 (FUNDC1) (5). The autophagosome maturation and fu-
sion with lysosome is mediated by Ras-associated pro-
tein 7, TBC1 domain family member 15 (TBC1D15), 
TBC1D17, homotypic fusion and protein sorting 
complex, pleckstrin homology and RUN domain contain-
ing M1, syntaxin-17, and vesicle-associated membrane 
protein 8 (3). Parkin-independent mitophagy occurs via 
BCL2 interacting protein (BNIP3), NIP3-like protein X (NIX), 
FUNDC1, BCL2 like 13, GABA(A) receptor-associated pro-
tein (GABARAP) and GABARAPL1 (5).
Mitophagy in heart disease
Mitophagy is crucial for heart function and development. 
The interruption of PINK1/MFN2/Parkin pathway in mice 
causes lethal cardiomyopathy by 7-8 weeks, while the sur-
viving mice exhibit abnormal energy metabolism in the 
heart (43).
Similarly to UPRmt, there is a fine line between protective 
and deleterious effects of mitophagy in cardiomyocytes. 
BNIP3 is transcriptionally up-regulated in the heart by hy-
poxia, whereas myocardial NIX up-regulation appears to 
be a specific transcriptional response to pathological hy-
pertrophy (44). Forced NIX expression in cardiomyocytes 
leads to progressive apoptotic cardiomyopathy and pre-
mature death (45). The ablation of BNIP3 reduces apopto-
sis in ischemic cardiomyocytes (46). A very similar effect in 
heart remodeling is observed in Nix knockout mice, which 
were protected from ventricular dilation, wall thinning, and 
systolic dysfunction following heart pressure overload (45). 
Conversely, Nix and Bnip3 double knockouts develop car-
diomyopathy with reduced ejection function of the left 
ventricle. This indicates that both NIX and BNIP3 may play 
a detrimental and beneficial role in the heart, depending 
on the (patho)physiological context and perhaps the ex-
tent of their activity.
Hypoxia activates FUNDC1, which interacts with LC3, there-
by, activating mitophagy in platelets, diminishing their ac-
tivity, which ameliorates cardiac reperfusion injury (47). 
The reduced levels of FUNDC1 (5) and PINK1 (41) are found 
in human samples of HF. Conversely, other studies show 
an elevated expression of mitophagy markers, including 
Parkin and LC3-mediated formation of autophagosome 
(42) and BNIP3 (48), in human and animal samples of HF 
of different etiologies. Cardiac-specific Fundc1 knockout 
mice exhibit impaired cardiac function, the accumulation 
of elongated and dysfunctional mitochondria and a great-
er degree of MI-induced HF (5). Similarly, PINK1-deficient 
mice are more susceptible to pressure overload-induced 
HF (41) and I/R heart injury (49). Moreover, the stimulation 
of PINK1/Parkin-mediated mitophagy by AMP-activated 
protein kinase α2 (AMPKα2) overexpression protects from 
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pressure-induced HF (50). Parkin overexpression protects 
the heart from aging-induced dysfunction and cell senes-
cence (51).
Mitochondrial function is unaffected in Parkin deficiency, 
although such mitochondria seem smaller, with a disor-
ganized network (52). However, Parkin-deficient mice are 
more sensitive to I/R injury, which can be reduced by Par-
kin overexpression in isolated cardiac myocytes (52). More-
over, ATG5 depletion induces HF (53), while ATG7 induc-
tion may ameliorate desmin-related cardiomyopathy (54). 
Impaired mitochondrial fusion-fission balance (55) and 
AMPKα2 (50,56) may lead to cardiomyopathy and/or cardi-
omyocyte necrosis in part by disrupting mitophagy. Phar-
macological and non-pharmacological mitophagy induc-
ers, such as rapamycin, mainly reduce cardiac I/R injury or 
pathological cardiac remodeling and HF (57).
Overall, similarly to UPRmt, studies have showed positive 
and negative effects of mitophagy in heart disease, which 
could be related to the extent of mitophagy activation.
MITOCHONDRIAL BIOgENESIS
Mitochondrial biogenesis is described in detail in the re-
view by Ploumi et al (58). In brief, mitochondrial biogenesis 
is driven to a lesser extent by mitochondrial DNA (mtDNA) 
and to a greater extent by nuclear DNA that harbors es-
sential regulatory processes. The key factors of mtDNA rep-
lication include mitochondrial DNA polymerase γ (POLG) 
and twinkle (resembles helicase) (59,60). POLG, mitochon-
drial transcription factor A (TFAM), and adenine nucleotide 
translocase (ANT) are important for mtDNA maintenance 
and repair (61-63). Mitochondrial DNA transcription elon-
gation factor defines whether replication or transcription 
takes place. The transcription initiation complex consists of 
TFAM, mitochondrial DNA-directed RNA polymerase, and 
mitochondrial dimethyladenosine transferase 2 enzyme 
(58). These transcription factors and coactivators regulate 
other processes, such as respiratory chain assembly or fat-
ty acid oxidation, and their impairment can affect cardiac 
function in multiple ways.
Nuclear respiratory factors 1 and 2 (NRF1 and NRF2) are 
transcription factors that regulate the expression of nu-
merous genes involved in mitochondrial assembly (64,65). 
NRF2 is negatively regulated by cytoplasmic protein KEAP1, 
which marks it for degradation by ubiquitination (58). The 
expression of genes involved in mitochondrial metabolism 
is controlled by estrogen related receptors (ERR)α and ERRγ, 
whereby ERRα activates peroxisome proliferator activated 
receptor (PPAR)α and up-regulates NRF1 (66-68). The cen-
tral role in the regulation of mitochondrial biogenesis be-
longs to PGC-1α. It is a transcription coactivator of PPARα, 
PPARβ, PPARγ, ERRα, ERRβ, ERRγ, NRF1 and NRF2 (69). A sim-
ilar role is played by PGC-1β (69).
Mitochondrial biogenesis in heart disease
An impaired mitochondrial biogenesis leads to HF and in-
creases the sensitivity to MI. A factor that interferes with 
mitochondrial biogenesis is ANT deficiency, which desta-
bilizes mtDNA, increases ROS production, and causes HF 
(63). Cardiac-specific Tfam knockout mice display reduced 
ATP generation, increased apoptosis, atrioventricular con-
duction block, and dilated cardiomyopathy (70-72). Con-
versely, TFAM overexpression protects the heart from MI-
induced HF (62). Similarly, the overexpression of TFAM or 
twinkle improves cardiac function in a pressure or volume 
overload and reduces ROS overproduction (59,60). Poor 
mtDNA replication and accumulation of mutations, in-
duced by inactive POLG, leads to dilated cardiomyopathy 
and interstitial fibrosis (61).
NRF1- or NRF2-deficient mice exhibit low levels of mtDNA, 
left ventricular dysfunction, and die before birth (64,65). 
Conversely, NRF2 induction by preconditioning or phar-
macological treatment protects against MI (73). ERRα-
deficient mice exhibit cardiac dysfunction only after pres-
sure overload (66), while ERRγ deficient mice exhibit lethal 
HF (67). The concomitant deletion of ERRα and ERRγ leads 
to prenatal death (74). While mice with prenatal knockout 
of either Pgc-1α or Pgc-1β experience mild cardiac dys-
function only after the exposure to noxious stimuli (75,76), 
prenatal knockouts of both proteins cause HF and prena-
tal death (69), indicating an overlap in their function. On 
the other hand, their deletion in adulthood is not associat-
ed with significant heart dysfunction (77). The same study 
also demonstrated that PGC-1α and PGC-1β deficiency 
decreases the expression of pro-fusion factors MFN2 and 
OPA1, and pro-fission factor fission 1 (FIS1), leading to ab-
normal mitochondrial morphology. This further shows 
multiple interplays among different MQC mechanisms. 
PGC-1α-induced biogenesis may act beneficially by reduc-
ing mitochondrial calcium uptake (78), which is a powerful 
stressor and inducer of mPTP opening (1,79). Mitochon-
drial permeability transition pore opening is induced by 
ROS and mitochondrial calcium overload and precedes 
cardiomyocyte death (80,81). However, in dilated (and 
not ischemic) cardiomyopathy, mitochondrial bio-
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genesis is enhanced (increased expression of PGC-1α, 
POLG, POLG2, and TFAM) (82). This possibly reflects a com-
pensatory response to mitochondrial dysfunction arising 
from mtDNA mutations that were the most prevalent in 
dilated cardiomyopathy (82). Conversely, in samples of HF 
with reduced ejection fraction, PGC-1α levels are reduced 
together with complex IV activity (48), which may suggest 
that poor biogenesis contributes to cardiac dysfunction.
Altogether, impaired mitochondrial biogenesis predispos-
es to HF and increases the extent of MI, while enhanced 
expression of biogenesis genes may correspond to com-
pensatory response to mitochondrial dysfunction.
MITOCHONDRIAL FUSION-FISSION BALANCE
Mitochondria constantly undergo fusion and fission. Mito-
chondrial dynamics is associated with the metabolic state 
of the cell, presence of various stressors, and other impor-
tant processes, such as cell proliferation and differentiation. 
Mitochondrial fusion-fission is reviewed in detail by Ježek 
et al (4). Fusion-fission dynamics work tightly with other 
MQC mechanisms, UPRmt, mitophagy and biogenesis.
The key protein responsible for mitochondrial fission is 
GTP-ase dynamin-related protein 1 (Drp1) (83). Other pro-
fission factors that interact with Drp1 and promote mito-
chondrial fission include FIS1 and mitochondrial dynam-
ics proteins mitochondrial dynamics protein of 49 KDa 
(MID49) and MID51 (4,84). Once activated, Drp1 translo-
cates from the cytoplasm onto mitochondria causing fis-
sion, which also requires the action of dynamin-2 (85). The 
mitochondrial fusion depends on three GTP-ases, MFN1, 
MFN2, and OPA1 (86,87). While MFN1 and MFN2 mediate 
OMM fusion, OPA1 mediates inner mitochondrial mem-
brane fusion. In addition to regulating the morphology 
of mitochondrial cristae, OPA1 also prevents apoptosis in 
physiological conditions, while pro-fission factors, such as 
Drp1, promote apoptosis (4,86,88). OMA1 and YME1L pro-
teases are key regulators of OPA1 activity, whereby OMA1 
cleaves and inactivates it (88).
Mitochondrial fusion-fission balance in heart disease
Extensive fission (fragmentation) of mitochondria has been 
associated with cardiac I/R injury (84,89), which is caused 
by enhanced FIS1 and Drp1 expression in mitochondria 
and/or reduced MFN1 and OPA1 expression (90). OPA1 
deficiency reduces mtDNA copy number, decreases mi-
tochondrial and heart function, and leads to cardio-
myopathy (91). Conversely, the induction of mitochondrial 
fusion by OPA1 overexpression protects cardiac (92) and 
other cell types (93) from various types of stressors. Zaja 
et al (83) showed that I/R injury induced mitochondrial fis-
sion, cardiomyocyte death and Drp1 activation (phospho-
rylation of Ser616 and dephosphorylation of Ser637), while 
it did not significantly change the expression of MFN1, 
MFN2 and OPA1. Drp1 activation results in cardiomyocyte 
death, with ROS and calcineurin acting as upstream mod-
ulators of Drp1 activity (83). Pharmacological Drp1 inhibi-
tion with mdivi-1 or calcineurin inhibition with FK506 re-
duces mitochondrial fission and cell death (83). Ong et al 
(84) have demonstrated that both the transfection of HL-1 
cells with the Mfn1, Mfn2, or a dominant-negative mutant 
form of Drp1 (Drp1K38A), or pharmacological Drp1 inhibi-
tion, promote mitochondrial elongation and reduce mPTP 
opening and cell death after simulated I/R injury. They also 
showed that human FIS1 overexpression reduced mito-
chondrial elongation, increased cell death, but without an 
effect on mPTP opening. Disatnik et al (89) used selective 
Drp1 inhibitor (P110) in ex vivo and in vivo rat heart model 
of MI to assess the role of Drp1/FIS1 interaction in reperfu-
sion injury. They found that increased mitochondrial frag-
mentation during reperfusion facilitated long-term cardiac 
dysfunction in rats, whereas acute inhibition of mitochon-
drial fission early at the onset of reperfusion resulted in 
long-term benefits. Conversely, FUNDC1 ablation promot-
ed mitochondrial elongation via FIS1 down-regulation, 
which caused mitochondrial dysfunction and HF in mice 
(5). Moreover, FUNDC1 and FIS1 are down-regulated and 
mitochondria are elongated in HF samples (5). This sug-
gests that the absence of mitochondrial fission and pre-
dominance of mitochondrial elongation (fusion) could be 
detrimental to the heart. However, this is inconsistent with 
the majority of other studies, which show an increase in 
mitochondrial fission in different types of HF and cardio-
myocyte injury (48,82,86). The expression of pro-fusion and 
pro-fission proteins varies among studies and types of HF. 
Ahuja et al (82) and Chen et al (86) found OPA1 decrease 
in ischemic heart and MFN2 increase in dilated cardiomy-
opathy. Conversely, these two studies found an opposite 
change in MFN2 in ischemic cardiomyopathy. In the first 
study it was decreased and in the second it was increased. 
In dilated cardiomyopathy, Ahuja et al found increased 
OPA1 and Chen et al found no change in OPA1. The lat-
ter study also found an increase in MFN1 and Drp1 and 
no change in FIS1 in both types of cardiomyopathy (86). 
Increased Drp1 expression was also found in the samples 
of HF with reduced ejection fraction (48). HF of different 
etiology in animal models is associated with increased mi-
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tochondrial fragmentation, decrease in pro-fusion factors, 
and increase in pro-fission factors: OPA1, MFN1, and Drp1 
(94); OPA1, MFN1, MFN2, Drp1, and FIS1 (87); MFN2 and 
Drp1 (95) and MFN2 (Drp1 was reduced) (42). In the major-
ity of these studies, mitochondrial fragmentation was asso-
ciated with elevated ROS generation, diminished ATP pro-
duction, and cardiac dysfunction/damage, while the shift 
toward mitochondrial fusion exhibited beneficial effects. 
Along these lines, Drp1 inhibition by mdivi-1 ameliorates 
the signs of HF arising from pressure overload (96). How-
ever, Drp1 is important for cardiac function. Its mutation 
causes HF due to impaired mitophagy, mitochondrial de-
polarization, poor calcium handling, and diminished ATP 
synthesis (97).
The majority of studies demonstrate beneficial effects of 
mitochondrial fusion and detrimental effects of fission in 
acute cardiac I/R injury, suggesting that mitochondrial fu-
sion increases the resistance to cell death possibly by at-
tenuating ROS generation and preserving ATP production. 
In chronic HF experiments, some of the results reported 
are not congruent with those by other investigators. In-
consistencies in results among studies testing human HF 
samples may arise from different reasons, such as method-
ological issues, biological variability of individuals/popula-
tions, and different etiologies of HF. Thus, a fusion-fission 
imbalance can lead to or accelerate HF, reflecting the im-
portance of both states for long term mitochondrial and 
cardiac function.
MITOCHONDRIAL QUALITY CONTROL IN THE AgED 
HEART
Aging is associated with a decline in cardiac function and 
increased incidence of MI and HF. Aging impairs mitochon-
drial function in part by dysregulation of MQC (98). Lim-
ited perturbations of mitochondrial function can induce 
UPRmt, a process that is associated with lifespan exten-
sion (99). Conversely, there are studies that demonstrate 
that triggering of UPRmt may reduce lifespan (99). UPRmt 
protease LON is down-regulated in aged cells (100). How-
ever, there is a lack of studies investigating UPRmt in the 
aged heart. The overexpression of ATG5 protein may ex-
tend lifespan (101), and its inhibition could lead to age-re-
lated cardiomyopathy in mice (102), suggesting that im-
pairment of autophagy/mitophagy could contribute to 
degenerative changes in the aged heart. Parallel ablation 
of MFN1, MFN2, and Drp1, which impaired mitochondri-
al dynamics, causes “mitochondrial senescence” and car-
diac changes that resemble aging-related cardiomyopa-
thy (103). In agreement to this study, Zhao et al found a 
reduced expression of p62, LC3-IIm PGC-1α and MFN2 in 
the aged (25-month-old) rat heart, indicating reduced au-
tophagy/mitophagy, mitochondrial biogenesis and fusion 
(104). Using 24-month-old mice, hearts Whitehead et al 
also found a reduced expression of MQC genes: PGC-1α, 
PGC-1β, TFAM, ERRα, MFN1, MFN2 and OPA1 but observed 
no change in FIS1 and Drp1 (105). Conversely, another 
study with older rats (36-months-old) showed elevated 
cardiac Drp1 and OPA1 expression (106).
Most of the existing studies suggest that the MQC is re-
duced in the aged heart and that its down-regulation 
shortens lifespan and leads to phenotypes found in the 
aged heart. However, there are data showing that some 
MQC components may be up-regulated in the aged heart. 
It is possible that, as in heart disease, MQC could exert ben-
eficial or maybe even detrimental effects in the aged heart. 
More studies are required to resolve such seemingly con-
flicting data.
CONCLUSIONS
MQC consists of several interconnected mechanisms that 
serve to maintain proper mitochondrial function. Nu-
merous studies demonstrate that failure in some of MQC 
mechanisms may induce HF or exacerbate MI, and that 
stimulation of MQC attenuates cardiac injury/dysfunction. 
On the contrary, a large number of studies also show that 
MQC elements are elevated in HF and that MQC down-
regulation has protective effects on the heart. It is possi-
ble that the effects of MQC on mitochondrial and cardiac 
functions are nonlinear or biphasic (107). In other words, a 
moderate activity of MQC may improve overall mitochon-
drial function and be beneficial for the heart as a compen-
satory response. However, hyperactive MQC could lead 
to excessive perturbation of mitochondrial homeostasis 
(eg, excessive mitochondrial removal or protein cleavage), 
leading to cardiac injury or exacerbating the existing path-
ological processes.
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